Startek (SRT) Stock Price, News & Analysis

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Startek in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRT, but not buy additional shares or sell existing shares.
View SRT analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price objectives for Startek's stock. Their SRT share price targets range from $4.00 to $5.50. On average, they predict the company's share price to reach $4.75 in the next year. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for SRT or view top-rated stocks among Wall Street analysts.

Startek, Inc. (NYSE:SRT) issued its quarterly earnings data on Tuesday, November, 2nd. The business services provider reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.03. The business services provider earned $172.79 million during the quarter, compared to the consensus estimate of $162.31 million. Startek had a positive trailing twelve-month return on equity of 12.22% and a negative net margin of 5.81%. During the same period last year, the company earned $0.01 earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Startek investors own include Amicus Therapeutics (FOLD), KeyCorp (KEY), SentinelOne (S), Vishay Intertechnology (VSH), Huntington Bancshares (HBAN), Kindred Biosciences (KIN), Mitek Systems (MITK), Pfizer (PFE) and